| Literature DB >> 29850820 |
Jelena-Rima Ghadri1, Ilan Shor Wittstein2, Abhiram Prasad3, Scott Sharkey4, Keigo Dote5, Yoshihiro John Akashi6, Victoria Lucia Cammann1, Filippo Crea7, Leonarda Galiuto7, Walter Desmet8,9, Tetsuro Yoshida10, Roberto Manfredini11, Ingo Eitel12, Masami Kosuge13, Holger M Nef14, Abhishek Deshmukh3, Amir Lerman3, Eduardo Bossone15, Rodolfo Citro15, Takashi Ueyama16, Domenico Corrado17, Satoshi Kurisu18, Frank Ruschitzka1, David Winchester19, Alexander R Lyon20,21, Elmir Omerovic22,23, Jeroen J Bax24, Patrick Meimoun25, Guiseppe Tarantini17, Charanjit Rihal3, Shams Y-Hassan26, Federico Migliore17, John D Horowitz27, Hiroaki Shimokawa28, Thomas Felix Lüscher29,30, Christian Templin1.
Abstract
The clinical expert consensus statement on takotsubo syndrome (TTS) part II focuses on the diagnostic workup, outcome, and management. The recommendations are based on interpretation of the limited clinical trial data currently available and experience of international TTS experts. It summarizes the diagnostic approach, which may facilitate correct and timely diagnosis. Furthermore, the document covers areas where controversies still exist in risk stratification and management of TTS. Based on available data the document provides recommendations on optimal care of such patients for practising physicians.Entities:
Mesh:
Year: 2018 PMID: 29850820 PMCID: PMC5991205 DOI: 10.1093/eurheartj/ehy077
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Overview of retrospective analyses, meta-analyses, and case series of medical management for takotsubo syndrome
| Authors | Study design | No. of patients | Outcome measures | Follow-up time | Medication | Effect |
|---|---|---|---|---|---|---|
| Santoro | Case series | 13 | Adverse events | During hospitalization | Levosimendan | Probably beneficial |
| Isogai | Retrospective | 2110 | Mortality | 30 days | β-Blockers | Not beneficial |
| Dias | Retrospective | 206 | MACE | During hospitalization | Antiplatelet | Beneficial |
| β-Blockers | Not beneficial | |||||
| Statins | Not beneficial | |||||
| ACEI | Not beneficial | |||||
| Templin | Retrospective | 1118 | Mortality | 1 year | β-Blockers | Not beneficial |
| ACEI/ARB | Beneficial | |||||
| Santoro | Meta-analysis | 511 | Recurrence | 24–60 months | β-Blockers | Not beneficial |
| ACEI/ARB | Not beneficial | |||||
| Aspirin | Not beneficial | |||||
| Statins | Not beneficial | |||||
| Singh | Meta-analysis | 847 | Recurrence | 19–33 months | β-Blockers | Not beneficial |
| ACEI/ARB | Beneficial |
Reprinted with permission from Kato et al.
ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; MACE, major adverse cardiac event.